Selected Publications
Jess J, Sorensen KM, Boguslawski EA, Stout MC, Madaj ZB, Caiello BP, Pomaville M, Wilson ER, Kinn-Gurzo SS, Parker CC, Veluvolu SM, Brysgel TV, Kaufman R, Kitchen-Goosen SM, Gedminas JM, Grohar PJ. Cell Context is the third axis of synergy for the combination of ATR inhibition and cisplatin in Ewing sarcoma. Clin Cancer Res. 2024 Mar 20. doi: 10.1158/1078-0432.CCR-23-3063. Epub ahead of print. PMID: 38506712.
Veluvolu SM, Grohar PJ. Importance of pharmacologic considerations in the development of targeted anticancer agents for children. Curr Opin Pediatr. 2023 Feb 1;35(1):91-96. doi: 10.1097/MOP.0000000000001208. Epub 2022 Dec 23. PMID: 36562272.
Shulman DS, Whittle SB, Surdez D, Bailey KM, de Álava E, Yustein JT, Shlien A, Hayashi M, Bishop AJR, Crompton BD, DuBois SG, Shukla N, Leavey PJ, Lessnick SL, Kovar H, Delattre O, Grünewald TGP, Antonescu CR, Roberts RD, Toretsky JA, Tirode F, Gorlick R, Janeway KA, Reed D, Lawlor ER, Grohar PJ. An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. NPJ Precis Oncol. 2022 Sep 17;6(1):65. doi: 10.1038/s41698-022-00307-2. PMID: 36115869; PMCID: PMC9482616.
Deng Q, Natesan R, Cidre-Aranaz F, Arif S, Liu Y, Rasool RU, Wang P, Mitchell-Velasquez E, Das CK, Vinca E, Cramer Z, Grohar PJ, Chou M, Kumar-Sinha C, Weber K, Eisinger-Mathason TSK, Grillet N, Grünewald T, Asangani IA. Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1. Cell Rep. 2022 Jun 14;39(11):110971. doi: 10.1016/j.celrep.2022.110971. PMID: 35705030.
Gedminas JM, Kaufman R, Boguslawski EA, Gross AC, Adams M, Beddows I, Kitchen-Goosen SM, Roberts RD, Grohar PJ. Lurbinectedin inhibits the EWS-WT1 transcription factor in desmoplastic small round cell tumor. Mol Cancer Ther. 2022 Jun 2:molcanther.1003.2021. doi: 10.1158/1535-7163.MCT-21-1003. Epub ahead of print. PMID: 35657345.
Maki RG, Grohar PJ, Antonescu CR. Ewing sarcoma and related FET family translocation-associated round cell tumors: A century of clinical and scientific progress. Genes Chromosomes Cancer. 2022 Apr 20. doi: 10.1002/gcc.23050. Epub ahead of print. PMID: 35443099.
Flores G, Grohar PJ. One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma. J Bone Oncol. 2021 Dec 1;31:100404. doi: 10.1016/j.jbo.2021.100404. PMID: 34976713; PMCID: PMC8686064
Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer. 2021;68(9):e29188. Epub 2021/06/18. doi: 10.1002/pbc.29188. PubMed PMID: 34137164; PMCID: PMC8316376.
Chasse MH, Johnson BK, Boguslawski EA, Sorensen KM, Rosien JE, Kang MH, Reynolds CP, Heo L, Madaj ZB, Beddows I, Foxa GE, Kitchen-Goosen SM, Williams BO, Triche TJ, Jr., Grohar PJ. Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor. EMBO Mol Med. 2021;13(2):e12640. Epub 2020/12/18. doi: 10.15252/emmm.202012640. PubMed PMID: 33332735; PMCID: PMC7863405.
Kinnaman MD, Zhu C, Weiser DA, Mohiuddin S, Hingorani P, Roth M, Gill J, Janeway KA, Gorlick R, Lessnick SL, Grohar PJ. Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology Group. Sarcoma. 2020;2020:3498549. Epub 2021/01/26. doi: 10.1155/2020/3498549. PubMed PMID: 33488267; PMCID: PMC7787769 advisor for Salarius Pharmaceuticals and has patents related to NKX2.2 and GSTM4 in Ewing sarcoma.
Gedminas JM, Chasse MH, McBrairty M, Beddows I, Kitchen-Goosen SM, Grohar PJ. Desmoplastic small round cell tumor is dependent on the EWS-WT1 transcription factor. Oncogenesis. 2020;9(4):41. Epub 2020/04/30. doi: 10.1038/s41389-020-0224-1. PubMed PMID: 32345977; PMCID: PMC7188842.
Flores G, Everett JH, Boguslawski EA, Oswald BM, Madaj ZB, Beddows I, Dikalov S, Adams M, Klumpp-Thomas CA, Kitchen-Goosen SM, Martin SE, Caplen NJ, Helman LJ, Grohar PJ. CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma. Mol Cancer Ther. 2020;19(5):1183-96. Epub 2020/03/05. doi: 10.1158/1535-7163.Mct-19-0775. PubMed PMID: 32127464.
Bailey K, Cost C, Davis I, Glade-Bender J, Grohar P, Houghton P, Isakoff M, Stewart E, Laack N, Yustein J, Reed D, Janeway K, Gorlick R, Lessnick S, DuBois S, Hingorani P. Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. F1000Res. 2019;8. Epub 2019/04/30. doi: 10.12688/f1000research.18139.1. PubMed PMID: 31031965; PMCID: PMC6468706.
Harlow ML, Chasse MH, Boguslawski EA, Sorensen KM, Gedminas JM, Kitchen-Goosen SM, Rothbart SB, Taslim C, Lessnick SL, Peck AS, Madaj ZB, Bowman MJ, Grohar PJ. Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner. Clin Cancer Res. 2019;25(11):3417-29. Epub 2019/02/07. doi: 10.1158/1078-0432.Ccr-18-3511. PubMed PMID: 30723142; PMCID: PMC6594545.
Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ, Widemann BC. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. Cancer Chemother Pharmacol. 2017;80(3):645-52. Epub 2017/07/25. doi: 10.1007/s00280-017-3382-x. PubMed PMID: 28735378; PMCID: PMC6413860.
Pridgeon MG, Grohar PJ, Steensma MR, Williams BO. Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors. Curr Osteoporos Rep. 2017;15(4):239-46. Epub 2017/06/26. doi: 10.1007/s11914-017-0377-9. PubMed PMID: 28647886.
Grohar PJ, Janeway KA, Mase LD, Schiffman JD. Advances in the Treatment of Pediatric Bone Sarcomas. Am Soc Clin Oncol Educ Book. 2017;37:725-35. Epub 2017/06/01. doi: 10.1200/edbk_175378. PubMed PMID: 28561686; PMCID: PMC6066791.
Herzog J, von Klot-Heydenfeldt F, Jabar S, Ranft A, Rossig C, Dirksen U, Van den Brande J, D'Incalci M, von Luettichau I, Grohar PJ, Berdel WE, Burdach S. Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity. Sarcoma. 2016;2016:7461783. Epub 2016/11/16. doi: 10.1155/2016/7461783. PubMed PMID: 27843394; PMCID: PMC5098094.
Harlow ML, Maloney N, Roland J, Guillen Navarro MJ, Easton MK, Kitchen-Goosen SM, Boguslawski EA, Madaj ZB, Johnson BK, Bowman MJ, D'Incalci M, Winn ME, Turner L, Hostetter G, Galmarini CM, Aviles PM, Grohar PJ. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus. Cancer Res. 2016;76(22):6657-68. Epub 2016/11/05. doi: 10.1158/0008-5472.Can-16-0568. PubMed PMID: 27697767; PMCID: PMC5567825.
Osgood CL, Tantawy MN, Maloney N, Madaj ZB, Peck A, Boguslawski E, Jess J, Buck J, Winn ME, Manning HC, Grohar PJ. (18)F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma. Sci Rep. 2016;6:33926. Epub 2016/09/28. doi: 10.1038/srep33926. PubMed PMID: 27671553; PMCID: PMC5037393.
Osgood CL, Maloney N, Kidd CG, Kitchen-Goosen S, Segars L, Gebregiorgis M, Woldemichael GM, He M, Sankar S, Lessnick SL, Kang M, Smith M, Turner L, Madaj ZB, Winn ME, Núñez LE, González-Sabín J, Helman LJ, Morís F, Grohar PJ. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. Clin Cancer Res. 2016;22(16):4105-18. Epub 2016/03/17. doi: 10.1158/1078-0432.Ccr-15-2624. PubMed PMID: 26979396; PMCID: PMC4987166.
Caropreso V, Darvishi E, Turbyville TJ, Ratnayake R, Grohar PJ, McMahon JB, Woldemichael GM. Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells. J Biol Chem. 2016;291(19):10058-66. Epub 2016/03/11. doi: 10.1074/jbc.M115.701375. PubMed PMID: 26961871; PMCID: PMC4858959.
Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Rédini F, Richter GH, Rossig C, Schadler K, Schäfer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Üren A, Zinovyev A, Delattre O. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget. 2016;7(8):8613-24. Epub 2016/01/24. doi: 10.18632/oncotarget.6937. PubMed PMID: 26802024; PMCID: PMC4890991.
Grohar PJ, Kim S, Rangel Rivera GO, Sen N, Haddock S, Harlow ML, Maloney NK, Zhu J, O'Neill M, Jones TL, Huppi K, Grandin M, Gehlhaus K, Klumpp-Thomas CA, Buehler E, Helman LJ, Martin SE, Caplen NJ. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma. Cell Rep. 2016;14(3):598-610. Epub 2016/01/19. doi: 10.1016/j.celrep.2015.12.063. PubMed PMID: 26776507; PMCID: PMC4755295.
Tancredi R, Zambelli A, DaPrada GA, Fregoni V, Pavesi L, Riccardi A, Burdach S, Grohar PJ, D'Incalci M. Targeting the EWS-FLI1 transcription factor in Ewing sarcoma. Cancer Chemother Pharmacol. 2015;75(6):1317-20. Epub 2015/03/27. doi: 10.1007/s00280-015-2726-7. PubMed PMID: 25809543.
Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res. 2014;20(5):1190-203. Epub 2013/11/28. doi: 10.1158/1078-0432.Ccr-13-0901. PubMed PMID: 24277455; PMCID: PMC5510643.
Borinstein SC, Beeler N, Block JJ, Gorlick R, Grohar P, Jedlicka P, Krailo M, Morris C, Phillips S, Siegal GP, Lawlor ER, Lessnick SL. A Decade in Banking Ewing Sarcoma: A Report from the Children's Oncology Group. Front Oncol. 2013;3:57. Epub 2013/03/23. doi: 10.3389/fonc.2013.00057. PubMed PMID: 23519678; PMCID: PMC3602933.
Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene. 2013;32(47):5429-38. Epub 2013/01/16. doi: 10.1038/onc.2012.590. PubMed PMID: 23318429; PMCID: PMC3898328.
Grohar PJ, Helman LJ. Prospects and challenges for the development of new therapies for Ewing sarcoma. Pharmacol Ther. 2013;137(2):216-24. Epub 2012/10/23. doi: 10.1016/j.pharmthera.2012.10.004. PubMed PMID: 23085431; PMCID: PMC7243921.
Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Currier DG, Davis S, Khanna C, Khan J, McMahon JB, Helman LJ. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening. J Natl Cancer Inst. 2011;103(12):962-78. Epub 2011/06/10. doi: 10.1093/jnci/djr156. PubMed PMID: 21653923; PMCID: PMC3119649.
Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia. 2011;13(2):145-53. Epub 2011/03/16. doi: 10.1593/neo.101202. PubMed PMID: 21403840; PMCID: PMC3033593.